Descripción de la empresa
Phaos Technology Holdings (Caym) Limited, operating through its subsidiary Phaos Technology Pte. Ltd., focuses on the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products within the Singapore market. The company operates within the Healthcare sector, specifically in the Medical Devices industry, which implies a focus on specialized equipment and instrumentation for medical diagnostics and research. As a small-cap entity, Phaos Technology Holdings holds a market capitalization of $21.93M and employs approximately 25 individuals to execute its operations. The reported annual revenue of $167,707 over the trailing twelve months indicates a very limited revenue base relative to the total market cap, suggesting the company is in an early-stage development phase or faces significant valuation premiums based on future potential rather than current earnings generation. This disparity between a small revenue stream and a substantial market capitalization highlights that the current valuation is driven largely by investor expectations for future product adoption rather than established profitability or cash flow from current sales.
Salud financiera
The financial statements for the trailing twelve months show a revenue of $167,707, a net income of $-5,137,064, and an EBITDA of $-3,869,313. The substantial gap between the modest revenue figure and the massive net loss reveals a highly inefficient cost structure where operating expenses significantly outweigh all income generated. The company reports a free cash flow of $-1,657,362, which indicates a severe lack of financial flexibility and a reliance on external capital sources to fund ongoing operations and research. Analysis of the three margin metrics reveals a gross margin of 22.1%, an operating margin of -1897.8%, and a profit margin of 0.0%. While the positive gross margin suggests that the cost of goods sold is less than the revenue per unit, the deeply negative operating margin indicates that administrative and research expenses are consuming far more than the gross profit generated. The balance sheet shows cash holdings of $177,660 against a total debt load of $3.26M, resulting in a debt-to-equity ratio that is listed as N/A due to the equity composition. This capital structure is highly leveraged in a traditional sense, as the company carries debt obligations that exceed its liquid cash reserves. Furthermore, a current ratio of 0.40 indicates that the company possesses only $0.40 in current assets for every $1.00 of current liabilities, signaling significant short-term liquidity constraints. Finally, the return on equity stands at -1073.1% and the return on assets is -71.2%, metrics that reveal management has been unable to generate any positive returns on the capital invested or assets employed, pointing to deep structural inefficiencies in the business model.
Evaluación de valoración
The valuation metrics present a complex picture with a P/E Ratio (TTM) of N/A and a Forward P/E of N/A, which implies that standard earnings-based valuation models cannot be applied due to the absence of positive earnings. The Price to Book ratio is listed at -27.23, a figure that mathematically indicates the market price is detached from the book value, often seen in distressed or highly speculative biotech and medical device firms where assets may not be fully utilized or are impaired. Additionally, the Price to Sales ratio is 130.77, which suggests the market is valuing the company at over 130 times its sales revenue, a multiple typically reserved for high-growth technology firms with proven scalability, whereas the EV/EBITDA is -11.44, further reflecting the negative earnings environment. The stock has traded between a 52-week high of $7.39 and a 52-week low of $0.53, meaning the current trading price sits somewhere within this wide volatility range. The Beta value is listed as N/A, which prevents a direct comparison of price volatility relative to the broader market index. These valuation anomalies, particularly the negative price-to-book and negative EV/EBITDA combined with high price-to-sales, suggest that traditional valuation anchors are failing to provide a clear signal of intrinsic value.
Growth & Income
The company experienced a revenue growth rate of -93.1% year-over-year, while earnings growth is listed as N/A due to the lack of comparable positive earnings periods. The negative revenue growth indicates a contraction in sales or a significant shift in the product lifecycle, suggesting the company is currently unable to sustain or expand its top line effectively. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Since the firm generates no earnings to distribute, the payout ratio is not applicable, and the company must instead rely on reinvesting its limited resources into research and development to achieve future growth. The overall growth and income profile is characterized by significant revenue contraction, negative cash flow, and a complete absence of dividend income or positive earnings growth, presenting a high-risk scenario for income-oriented investors or those seeking capital appreciation based on current performance.